Cargando…

507. Impact of Baricitinib on Outcomes in Patients Treated with Remdesivir and Dexamethasone for SARS-CoV-2 Pneumonia: A Retrospective Cohort Study

BACKGROUND: There is a lack of data specifically addressing the effects of triple therapy consisting of baricitinib plus remdesivir plus dexamethasone compared to dual therapy with remdesivir plus dexamethasone among patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) pneumoni...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dea, Lauren, Piwonka, Hal, Gonzales, Learned, Kerkar, Shubha, Mdluli, Xolani, Kim, Yisu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2021
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8644669/ http://dx.doi.org/10.1093/ofid/ofab466.706

Ejemplares similares

A Retrospective Study of Dexamethasone, Remdesivir, and Baricitinib in Severe COVID-19
por: Ngo, Dallis Q., et al.
Publicado: (2022)

COVID-19-Associated Pulmonary Aspergillosis in a Patient Treated With Remdesivir, Dexamethasone, and Baricitinib: A Case Report
por: Shimada, Ayako, et al.
Publicado: (2022)

Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19
por: Izumo, Takehiro, et al.
Publicado: (2021)

Efficacy of the combination of baricitinib, remdesivir, and dexamethasone in hypoxic adults with COVID-19: A retrospective study
por: Yasuda, Yuto, et al.
Publicado: (2022)

Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19
por: Kalil, Andre C., et al.
Publicado: (2020)

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis
por: Pérez-Alba, Eduardo, et al.
Publicado: (2021)

Perspectives of association Baricitinib/Remdesivir for adults with Covid-19 infection
por: Vitiello, Antonio, et al.
Publicado: (2021)

REMDESIVIR PLUS DEXAMETHASONE VS TOCILIZUMAB OR BARICITINIB SUPPLEMENTATION INITIATED INSIDE 48 HOURS OF INDEX COVID-19 HOSPITALIZATION IN ICU PATIENTS
por: WILLIAMS, STEPHANIE N, et al.
Publicado: (2022)

498. Baricitinib in Patients with Severe Pneumonia due to COVID-19 in Veracruz, Mexico
por: Del Carpio-Orantes, Luis, et al.
Publicado: (2021)

Combination therapy with predicted body weight-based dexamethasone, remdesivir, and baricitinib in patients with COVID-19 pneumonia: A single-center retrospective cohort study during 5th wave in Japan
por: Hirasawa, Yasutaka, et al.
Publicado: (2023)

P507: SALVAGE THERAPY WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE, HOMOHARRINGTONINE AND CYTARABINE IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
por: Yuan, Linyu, et al.
Publicado: (2023)

SAT-507 Pneumocystis Carinii Pneumonia: A Rare Cause of Granulomatous Hypercalcemia
por: Kumar, Swati, et al.
Publicado: (2019)

Use of Baricitinib in Combination With Remdesivir and Steroid in COVID-19 Treatment: A Multicenter Retrospective Study
por: So, Jessica M, et al.
Publicado: (2021)

Crystal structure of domain of unknown function 507 (DUF507) reveals a new protein fold
por: McKay, Cole E., et al.
Publicado: (2023)

Dexamethasone/remdesivir: Acute pancreatitis: case report
Publicado: (2022)

Séminaire Bourbaki : exposés 507–524
por: Dold, A, et al.
Publicado: (1979)

507. Activation of Macrophages Enhances Susceptibility to SARS-CoV-2 Antibody-Dependent Enhancement and Promotes Damage to Downstream Epithelial Cells
por: DeMarco, Jennifer K, et al.
Publicado: (2020)

Dexamethasone/propofol/remdesivir: Various toxicities: case report
Publicado: (2021)

Antibacterials/dexamethasone/remdesivir: Lack of efficacy: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Various toxicities: case report
Publicado: (2022)

Dexamethasone/remdesivir/tocilizumab: Lack of efficacy: case report
Publicado: (2022)

Fewer COVID‐19 Neurological Complications with Dexamethasone and Remdesivir
por: Grundmann, Alexander, et al.
Publicado: (2022)

Dexamethasone/remdesivir: Derangement of liver function tests, pneumocystis pneumonia and off-label use: case report
Publicado: (2022)

527. Lower Risk of ICU Admission with Remdesivir in Patients Hospitalized with COVID-19 Pneumonia
por: Lim, Sarah, et al.
Publicado: (2021)

545. A Retrospective Review of 30-day Mortalities in Solid-Organ Transplant Recipients (SOT) versus Non-Transplant Patients (NTP) Receiving Remdesivir (REM) and Dexamethasone (DEX) for COVID-19 Pneumonia
por: Vyas, Krina, et al.
Publicado: (2021)

Initiation of Tocilizumab or Baricitinib Were Associated With Comparable Clinical Outcomes Among Patients Hospitalized With COVID-19 and Treated With Dexamethasone
por: Wong, Carlos K. H., et al.
Publicado: (2022)

Cost-Effectiveness of Combination of Baricitinib and Remdesivir in Hospitalized Patients with COVID-19 in the United States: A Modelling Study
por: Kelton, Kari, et al.
Publicado: (2021)

Severe COVID-19 Pneumonia in an Unvaccinated Female Treated With Remdesivir
por: Ortega, Kaylee, et al.
Publicado: (2022)

Prognostic factors of 30-day mortality in patients with COVID-19 pneumonia under standard remdesivir and dexamethasone treatment
por: Choi, Yu Jung, et al.
Publicado: (2022)

Successful recovery from COVID-19 pneumonia after receiving baricitinib, tocilizumab, and remdesivir. A case report: Review of treatments and clinical role of computed tomography analysis
por: Sodani, Pietro, et al.
Publicado: (2020)

Dexamethasone/remdesivir: Lack of efficacy and drug withdrawal: case report
Publicado: (2022)

Viable SARS-CoV-2 shedding under remdesivir and dexamethasone treatment
por: Yoon, Jin Gu, et al.
Publicado: (2022)

Association and pharmacological synergism of the triple drug therapy baricitinib/remdesivir/rhACE2 for the management of COVID-19 infection
por: Vitiello, Antonio, et al.
Publicado: (2021)

Safety and Efficacy of Combination Therapy of Remdesivir, Baricitinib, and High-dose Steroids in Patients Hospitalized with Moderate to Severe COVID-19
por: Nagasawa, Ryo, et al.
Publicado: (2023)

73. Geographical Disparities in Clinical Outcomes of Severe COVID-19 Patients Treated with Remdesivir
por: Diaz, George, et al.
Publicado: (2020)

Baricitinib/dexamethasone: Myalgia and elevated creatine kinase following an off-label use: case report
Publicado: (2022)

Oral Bioactive Self-Nanoemulsifying Drug Delivery Systems of Remdesivir and Baricitinib: A Paradigmatic Case of Drug Repositioning for Cancer Management
por: Kazi, Mohsin, et al.
Publicado: (2023)

Baricitinib Therapy in Covid-19 Pneumonia — An Unmet Need Fulfilled
por: Goletti, Delia, et al.
Publicado: (2021)

Cost-effectiveness of Remdesivir and Dexamethasone for COVID-19 Treatment in South Africa
por: Jo, Youngji, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_hqtk5bu96lvjsteqohp6jqc0n0